SG10201400422QA - Antibodies to ox-2/cd200 and uses thereof - Google Patents

Antibodies to ox-2/cd200 and uses thereof

Info

Publication number
SG10201400422QA
SG10201400422QA SG10201400422QA SG10201400422QA SG10201400422QA SG 10201400422Q A SG10201400422Q A SG 10201400422QA SG 10201400422Q A SG10201400422Q A SG 10201400422QA SG 10201400422Q A SG10201400422Q A SG 10201400422QA SG 10201400422Q A SG10201400422Q A SG 10201400422QA
Authority
SG
Singapore
Prior art keywords
cd200
ox
antibodies
uses
Prior art date
Application number
SG10201400422QA
Inventor
Katherine S Bowdish
Anke Kretz-Rommel
Mcknight Susan Faas
Jeremy P Springhorn
Dayang Wu
Original Assignee
Alexion Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US75842606P priority Critical
Priority to US75908506P priority
Priority to US80199106P priority
Application filed by Alexion Pharma Inc filed Critical Alexion Pharma Inc
Publication of SG10201400422QA publication Critical patent/SG10201400422QA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
SG10201400422QA 2006-01-12 2007-01-11 Antibodies to ox-2/cd200 and uses thereof SG10201400422QA (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US75842606P true 2006-01-12 2006-01-12
US75908506P true 2006-01-12 2006-01-12
US80199106P true 2006-05-18 2006-05-18

Publications (1)

Publication Number Publication Date
SG10201400422QA true SG10201400422QA (en) 2014-05-29

Family

ID=38068567

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201400426XA SG10201400426XA (en) 2006-01-12 2007-01-11 Antibodies to ox-2/cd200 and uses thereof
SG10201400422QA SG10201400422QA (en) 2006-01-12 2007-01-11 Antibodies to ox-2/cd200 and uses thereof

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201400426XA SG10201400426XA (en) 2006-01-12 2007-01-11 Antibodies to ox-2/cd200 and uses thereof

Country Status (21)

Country Link
US (3) US8075884B2 (en)
EP (3) EP2463305B1 (en)
JP (3) JP5404052B2 (en)
KR (2) KR101459159B1 (en)
CN (1) CN103690947A (en)
AU (1) AU2007207764B2 (en)
BR (1) BRPI0707126A2 (en)
CA (1) CA2636577C (en)
DK (1) DK2463305T3 (en)
ES (2) ES2709672T3 (en)
HU (1) HUE028179T2 (en)
IL (1) IL192668A (en)
MX (1) MX2008009015A (en)
NZ (2) NZ599035A (en)
PL (1) PL2463305T3 (en)
PT (1) PT2463305T (en)
RU (2) RU2520088C2 (en)
SG (2) SG10201400426XA (en)
SI (1) SI2463305T1 (en)
TW (1) TW200804422A (en)
WO (1) WO2007084321A2 (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US9249229B2 (en) 2000-12-08 2016-02-02 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20060057651A1 (en) 2000-12-08 2006-03-16 Bowdish Katherine S Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
SI2463305T1 (en) * 2006-01-12 2016-10-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
WO2007114319A1 (en) * 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha Method for control of blood kinetics of antibody
AR061317A1 (en) 2006-06-08 2008-08-20 Chugai Pharmaceutical Co Ltd Agents for preventing or treating inflammatory diseases
MX2009007284A (en) * 2007-01-11 2009-10-08 Boehringer Ingelheim Int Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts.
WO2009004339A2 (en) * 2007-07-03 2009-01-08 Imperial Innovations Limited Modulation of reactive oxygen species in the treatment of respiratory infection
MX2010000979A (en) * 2007-07-25 2010-03-26 Alexion Pharma Inc Methods and compositions for treating autoimmune disease.
WO2009014745A1 (en) * 2007-07-25 2009-01-29 Alexion Pharmaceuticals, Inc. Antibodies to cd200 and uses thereof in inhibiting immune responses
PL2202245T3 (en) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substitution in cdr
EP3059246B1 (en) * 2007-09-26 2018-07-11 Chugai Seiyaku Kabushiki Kaisha Modified antibody constant region
DK2783692T3 (en) * 2007-09-28 2019-04-15 Celularity Inc Tumor suppression using humant placenta perfusate and human placenta derivative intermediate natural killer cells
ES2585480T3 (en) * 2007-12-05 2016-10-06 Chugai Seiyaku Kabushiki Kaisha anti-NR10 antibody and use thereof
CA2720294A1 (en) 2008-04-04 2009-10-08 Trillium Therapeutics Inc. Assay for soluble cd200
CN101592668B (en) 2008-05-31 2012-10-24 刘秀梅 Method for quantitatively measuring content of estradiol in extracts of Chinese medicine herbs
EP2826789A1 (en) 2009-03-19 2015-01-21 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
JP5717624B2 (en) 2009-03-19 2015-05-13 中外製薬株式会社 Antibody constant region variants
AU2011203879A1 (en) * 2010-01-11 2012-08-02 Alexion Pharmaceuticals, Inc. Biomarkers of immunomodulatory effects in humans treated with anti-CD200 antibodies
RU2012138703A (en) 2010-02-11 2014-03-20 Алексион Фармасьютикалз, Инк. Therapeutic and diagnostic methods using anti-cd200 antibodies
PL2663579T3 (en) 2011-01-14 2017-09-29 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
US9447187B2 (en) 2011-02-03 2016-09-20 Alexion Pharmaceuticals, Inc. Use of an anti-CD200 antibody for prolonging the survival of allografts
WO2012167346A1 (en) 2011-06-10 2012-12-13 Her Majesty The Queen In Right Of Canada, As Represented By The Minister Of National Defence Anti-ricin antibodies and uses thereof
TW201835108A (en) 2013-02-01 2018-10-01 美商再生元醫藥公司 Antibodies comprising chimeric constant domains
US20180215801A1 (en) 2015-01-29 2018-08-02 Board Of Trustees Of Michigan State University Cryptic polypeptides and uses thereof
WO2017079335A1 (en) * 2015-11-03 2017-05-11 Regents Of The University Of Minnesota Cd200 inhibitors and methods of use thereof
CN109475602A (en) 2016-06-20 2019-03-15 科马布有限公司 Anti- PD-L1 and IL-2 cell factor
WO2018075408A1 (en) 2016-10-17 2018-04-26 Alexion Pharmaceuticals, Inc. Methods of treating acute myeloid leukemia (aml) with combinations of anti-cd200 antibodies, cytarabine, and daunorubicin
WO2018102594A1 (en) * 2016-12-01 2018-06-07 Alexion Pharmaceuticals, Inc. Methods of treating solid tumors with anti-cd200 antibodies
WO2019067499A1 (en) 2017-09-27 2019-04-04 Alexion Pharmaceuticals, Inc. Biomarker signature for predicting tumor response to anti-cd200 therapy
WO2019126133A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals, Inc. Liquid formulations of anti-cd200 antibodies
WO2019126536A1 (en) * 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3940475A (en) 1970-06-11 1976-02-24 Biological Developments, Inc. Radioimmune method of assaying quantitatively for a hapten
US4289747A (en) 1978-12-26 1981-09-15 E-Y Laboratories, Inc. Immunological determination using lectin
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
DE3307869A1 (en) 1983-03-05 1984-09-06 Dragoco Gerberding Co Gmbh Substituted Methyl 1 - ((3-methylthio) -1-oxo-butyl) cyclohex-2-ene, processes for their preparation and their use as fragrances and aromas,
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4634666A (en) 1984-01-06 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Human-murine hybridoma fusion partner
AT68703T (en) 1984-02-08 1991-11-15 Cetus Corp Toxin conjugates.
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5092885A (en) 1987-02-12 1992-03-03 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Peptides with laminin activity
DE3852304D1 (en) 1987-03-02 1995-01-12 Enzon Lab Inc Organism as a support for "Single Chain Antibody domain (SCAD)".
JP3101690B2 (en) 1987-03-18 2000-10-23 エス・ビィ・2・インコーポレイテッド Denaturation antibody, or improvements relating modified antibody
JPH0246297A (en) 1988-08-08 1990-02-15 Takeda Chem Ind Ltd Production of monoclonal antibody, antibody-producing hybridoma and antibody
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US5192744A (en) 1990-01-12 1993-03-09 Northwestern University Method of inhibiting angiogenesis of tumors
EP0652950B1 (en) 1992-07-24 2007-12-19 Amgen Fremont Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US20050287630A1 (en) 1995-04-27 2005-12-29 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991010741A1 (en) 1990-01-12 1991-07-25 Cell Genesys, Inc. Generation of xenogeneic antibodies
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
DE69114782T2 (en) 1990-08-08 1996-04-18 Takeda Chemical Industries Ltd Intravascular embolizing agent with a content of the angiogenesis inhibiting substance.
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US7041871B1 (en) 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
WO1994025585A1 (en) 1993-04-26 1994-11-10 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
DE69127627D1 (en) 1990-08-29 1997-10-16 Genpharm Int Production and Nützung nonhuman transgentiere heterologous antibody production
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
CA2090473A1 (en) 1990-08-29 1992-03-01 Robert M. Kay Homologous recombinatin in mammalian cells
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0564531B1 (en) 1990-12-03 1998-03-25 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5780279A (en) 1990-12-03 1998-07-14 Genentech, Inc. Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
AU1411992A (en) 1991-01-15 1992-08-27 Robert A Bok A composition containing a tetracycline and use for inhibiting angiogenesis
WO1992022670A1 (en) 1991-06-12 1992-12-23 Genpharm International, Inc. Early detection of transgenic embryos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
CA2110518C (en) 1991-06-27 2007-05-22 Peter S. Linsley Ctla4 receptor, fusion proteins containing it and uses thereof
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5728815A (en) 1992-03-30 1998-03-17 Board Of Regents, The University Of Texas System Bone and prostate-derived protein factors affecting prostate cancer growth, differentiation, and metastasis
NZ253943A (en) 1992-06-18 1997-01-29 Genpharm Int Transfering polynucleotides into eukaryotic cells using co-lipofection complexes of a cationic lipid and the polynucleotide
US5508717A (en) 1992-07-28 1996-04-16 Sony Corporation Computer pointing device with dynamic sensitivity
US6228879B1 (en) 1997-10-16 2001-05-08 The Children's Medical Center Methods and compositions for inhibition of angiogenesis
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US6573256B2 (en) 1996-12-30 2003-06-03 Bone Care International, Inc. Method of inhibiting angiogenesis using active vitamin D analogues
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US6335160B1 (en) 1995-02-17 2002-01-01 Maxygen, Inc. Methods and compositions for polypeptide engineering
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
US5686292A (en) 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
DE69621940D1 (en) 1995-08-18 2002-07-25 Morphosys Ag Protein-/(poly)peptidbibliotheken
WO1997015666A1 (en) 1995-10-23 1997-05-01 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
AU7503296A (en) 1995-10-31 1997-05-22 University Of Alabama At Birmingham Research Foundation, The Genetic induction of receptors for targeted radiotherapy
WO1997021450A1 (en) 1995-12-08 1997-06-19 Brigham And Women's Hospital, Inc. Ox-2 costimulatory molecule
US5837682A (en) 1996-03-08 1998-11-17 The Children's Medical Center Corporation Angiostatin fragments and method of use
PT892643E (en) 1996-03-20 2002-09-30 Univ Emory Methods for inhibiting an immunity response blocking the gp39 / cd40 and ctla4 / cd28 / b7 circuits and uses for the effect
US6500924B1 (en) 1996-05-31 2002-12-31 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6011138A (en) 1997-02-20 2000-01-04 Idec Pharmaceuticals Corporation Gamma-1 anti-human CD23 monoclonal antibodies
WO1998047531A2 (en) 1997-04-21 1998-10-29 Arch Development Corporation Fc receptor non-binding anti-cd3 monoclonal antibodies deliver a partial tcr signal and induce clonal anergy
US6955811B2 (en) 1997-11-07 2005-10-18 Trillium Therapeutics Inc. Methods of inhibiting immune response suppression by administering antibodies to OX-2
US7223729B2 (en) 1997-11-07 2007-05-29 Trillium Therapeutics Inc. Methods of treating allergy by administering a CD200 protein
WO1999024565A1 (en) 1997-11-07 1999-05-20 Transplantation Technologies Inc. Methods and compositions for immunomodulation
US6475784B1 (en) 1997-11-14 2002-11-05 Valentis, Inc. Inhibition of angiogenesis by delivery of nucleic acids encoding anti-angiogenic polypeptides
EP1048673A4 (en) 1997-12-26 2002-10-25 Mochida Pharm Co Ltd Neovascularization inhibitor containing dienogest as the active ingredient
DK1068241T3 (en) 1998-04-02 2008-02-04 Genentech Inc Antibody variants and fragments thereof
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
CA2331620A1 (en) 1998-05-11 1999-11-18 The Endowment For Research In Human Biology, Inc. Use of neomycin for treating angiogenesis-related diseases
US6413513B1 (en) 1998-05-22 2002-07-02 Entremed, Inc. Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers
DE19829473C2 (en) 1998-07-01 2000-08-10 Magnus Von Knebel Doeberitz Ch Method for the early diagnosis of carcinomas
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
AU772778B2 (en) 1998-07-13 2004-05-06 University Of Southern California Novel inhibitors of angiogenesis and tumor growth
CA2337231A1 (en) 1998-07-14 2000-01-27 Bristol-Myers Squibb Company Lysine binding fragments of angiostatin
EP1119252A4 (en) 1998-08-21 2004-03-03 Childrens Medical Center Use of melanin for inhibition of angiogenesis and macular degeneration
US6045501A (en) 1998-08-28 2000-04-04 Celgene Corporation Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US6737056B1 (en) * 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20020192215A1 (en) 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
US6465431B1 (en) 1999-11-17 2002-10-15 Boston Life Sciences, Inc. Pharmaceutical compositions comprising troponin subunits, fragments and homologs thereof and methods of their use to inhibit angiogenesis
US6680209B1 (en) 1999-12-06 2004-01-20 Biosite, Incorporated Human antibodies as diagnostic reagents
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US7291330B2 (en) 2000-03-17 2007-11-06 Trillium Therapeutics Inc. MD-1 inhibitors as immune suppressants
EP1268544A2 (en) 2000-03-31 2003-01-02 Centre National De La Recherche Scientifique Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof
US7306801B2 (en) 2000-05-15 2007-12-11 Health Research, Inc. Methods of therapy for cancers characterized by overexpression of the HER2 receptor protein
AU7833801A (en) 2000-08-03 2002-02-18 Reginald M Gorczynski Methods and compositions for modulating tumor growth
US20030017491A1 (en) 2000-09-14 2003-01-23 Zuo-Rong Shi Chromogenic in situ hybridization methods, kits, and compositions
US6548477B1 (en) 2000-11-01 2003-04-15 Praecis Pharmaceuticals Inc. Therapeutic agents and methods of use thereof for the modulation of angiogenesis
AT406385T (en) 2000-11-22 2008-09-15 Trillium Therapeutics Inc Shorten cd200
CA2434237C (en) * 2000-12-07 2012-05-15 Eli Lilly And Company Glp-1 fusion proteins
US7408041B2 (en) * 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
US20040198661A1 (en) 2000-12-08 2004-10-07 Bowdish Katherine S. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
WO2002059280A2 (en) 2000-12-08 2002-08-01 Alexion Pharmaceuticals, Inc. Chronic lymphocytic leukemia cell line and its use for producing an antibody
EP1366455B1 (en) 2001-02-19 2008-07-02 MERCK PATENT GmbH Method for identification of t-cell epitopes and use for preparing molecules with reduced immunogenicity
US6590059B2 (en) 2001-05-11 2003-07-08 Ap Pharma, Inc. Bioerodible polyorthoesters from dioxolane-based diketene acetals
US7368535B2 (en) 2001-05-24 2008-05-06 Trillium Therapeutics Inc. CD200 receptors
AT448320T (en) 2001-09-19 2009-11-15 Alexion Pharma Inc Manipulated matrices and their use in single primer amplification
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
CA2624189A1 (en) 2005-10-03 2007-04-12 Xencor, Inc. Fc variants with optimized fc receptor binding properties
CA2511513A1 (en) 2002-12-27 2004-07-22 Schering Corporation Methods of inducing and maintaining immune tolerance
US20070009957A1 (en) 2003-03-04 2007-01-11 Alexion Pharmaceuticals, Inc. Vectors used to create hybrid constant regions
CA2527878A1 (en) * 2003-05-30 2005-01-27 Alexion Pharmaceuticals, Inc. Antibodies and fusion proteins that include engineered constant regions
EP1658095A4 (en) 2003-06-02 2006-06-14 Alexion Pharma Inc De-immunized anti-cd3 antibody
JP2007500508A (en) 2003-07-29 2007-01-18 モルフォテック、インク. Methods for producing recombinant antibodies with enhanced antibody and effector functions
US6953417B2 (en) * 2003-11-17 2005-10-11 Borgwarner Inc. Method for controlling a dual clutch transmission
CA2554628A1 (en) * 2004-02-02 2005-08-18 Schering Corporation Methods of modulating cd200 and cd200r
TWI409078B (en) 2004-06-02 2013-09-21 Sidney Kimmel Cancer Ct Tissue-specific imaging and therapeutic agents targeting proteins expressed on lung endothelial cell surface
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
US20070036786A1 (en) 2005-07-11 2007-02-15 Nadine Tuaillon Method of treating autoimmune disease using humanized anti-CD16A antibodies
SI2463305T1 (en) 2006-01-12 2016-10-28 Alexion Pharmaceuticals, Inc. Antibodies to OX-2/CD200 and uses thereof
US20080131428A1 (en) 2006-02-24 2008-06-05 Arius Research, Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
MX2009007284A (en) 2007-01-11 2009-10-08 Boehringer Ingelheim Int Cd200 and its receptor, cd200r, modulate bone mass via the differentiation of osteoclasts.
US9306926B2 (en) 2013-03-15 2016-04-05 Brian A. Truong User authentication using unique hidden identifiers

Also Published As

Publication number Publication date
SG10201400426XA (en) 2014-07-30
KR20140091765A (en) 2014-07-22
US8709415B2 (en) 2014-04-29
RU2013152730A (en) 2015-06-10
PT2463305T (en) 2016-07-19
EP3101033B1 (en) 2019-01-02
JP5911391B2 (en) 2016-04-27
CA2636577C (en) 2015-09-15
IL192668A (en) 2014-11-30
RU2008133032A (en) 2010-02-20
AU2007207764B2 (en) 2012-06-07
BRPI0707126A2 (en) 2011-04-19
NZ569903A (en) 2012-07-27
SI2463305T1 (en) 2016-10-28
EP2463305A1 (en) 2012-06-13
JP2009528263A (en) 2009-08-06
EP2463305B1 (en) 2016-05-11
JP5404052B2 (en) 2014-01-29
MX2008009015A (en) 2009-01-07
HUE028179T2 (en) 2016-12-28
KR20080099262A (en) 2008-11-12
US9000133B2 (en) 2015-04-07
CA2636577A1 (en) 2007-07-26
IL192668D0 (en) 2009-02-11
AU2007207764A1 (en) 2007-07-26
DK2463305T3 (en) 2016-08-29
KR101459159B1 (en) 2014-11-12
US20120148579A1 (en) 2012-06-14
US20130172534A1 (en) 2013-07-04
EP1984403A2 (en) 2008-10-29
EP3101033A1 (en) 2016-12-07
JP2012193215A (en) 2012-10-11
WO2007084321A2 (en) 2007-07-26
US20100285030A1 (en) 2010-11-11
WO2007084321A3 (en) 2007-11-08
JP2014156487A (en) 2014-08-28
PL2463305T3 (en) 2017-02-28
ES2586825T3 (en) 2016-10-19
US8075884B2 (en) 2011-12-13
CN103690947A (en) 2014-04-02
ES2709672T3 (en) 2019-04-17
RU2520088C2 (en) 2014-06-20
NZ599035A (en) 2013-12-20
TW200804422A (en) 2008-01-16

Similar Documents

Publication Publication Date Title
DK2129396T3 (en) Antibodies to ErbB3 and uses thereof
DK2032606T3 (en) Antibodies and immune conjugates and uses thereof
TWI561530B (en) Antibodies to il-6 and use thereof
DK1994055T3 (en) Anti-5t4 antibodies and applications thereof
GB0606263D0 (en) Assay methods and devices
IL187106A (en) Sclerostin-binding antibody
RU2007132876A (en) Antibodies to dr5 and their applications
IL234081A (en) Cross - species - specific cd3 - epsilon binding antibody
EP2077859A4 (en) Antibody formulation
ZA200901402B (en) Antibodies to il-17a
ZA200901617B (en) High affinity human antibodies to human IL-4 receptor
EP2436696B8 (en) Anti-beta-amyloid antibody and uses thereof
SI1904104T1 (en) Sp35 antibodies and uses thereof
IL190472D0 (en) Anti-glypican-3 antibody
DK2064239T3 (en) Anti-activin a antibodies and uses thereof
HK1200856A1 (en) Anti mesothelin antibodies and uses therefor
SG10201605394SA (en) Modified Antibody Constant Region
HK1120273A1 (en) Anti-fgf19 antibodies and methods using same fgf19
IL184659D0 (en) Antibody variants and uses thereof
HRP20141249T1 (en) Antibody formulation
SG2014013437A (en) Monoclonal antibodies and uses thereof
IL215027D0 (en) ANTI-zB7R1 ANTIBODY
ZA201003759B (en) Antibodies against human nkg2d and uses thereof
HK1207387A1 (en) Anti-pd-l1 antibodies and their use to enhance t-cell function -pd-l1 t
RS55740B1 (en) Human antibodies that bind cxcr4 and uses thereof